Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Taking an informed look at Cinvanti IV, Heron’s complementary drug to Sustol in Chemotherapy-Induced Nausea & Vomiting after Nov 9th approval

Ticker(s): HRTX, MRK

Who's the expert?

Name: Joseph Bubalo, Pharm.D. BCPS, BCOP

Institution: Oregon Health & Science University Hospital

  • Oncology pharmacotherapy specialist with OHSU & Assistant Professor of Medicine with the Division of Hematology and Medical Oncology. 
  • Active in the clinical care of oncology and HSCT patients for over 20 years and has received research grants investigating ways to improve the control of nausea and vomiting as well as a variety of other topics in supportive care and infectious disease. 
  • Has served as PI for CINV trials and research focuses on novel approaches to decrease the symptoms associated with antineoplastic and surgical therapies. 
  • Clinical Operations Manager who represents the department on many multidisciplinary committees and his administrative interests include improving systems of care, patient safety, and clinical pharmacy service development.

Interview Questions
Q1.

Please describe your clinical practice, How many patients with CINV do you currently treat?

Added By: c_admin
Q2.

Please describe the first-line treatment you use and the risk factors associated with CINV.

Added By: c_admin
Q3.

What are the main differences between the company’s already approved Sustol and Cinvanti? In your opinion could these serve as complementary drugs?

Added By: c_admin
Q4.

After being rejected 3 times since 2010, Sustol finally got approved in 2016 for CINV. Do you currently use Sustol? What are the chances of Cinvanti being frequently used as an adjunct to other antiemetic agents, in your practice? Would you switch patients from other therapies?

Added By: c_admin
Q5.

How big of an impact does Cinvanti’s exclusion of synthetic surfactants have, as compared to the drugs it is trying to compete with such as Emend IV?

Added By: c_admin
Q6.

What is the current need for CINV therapies. As chemo regimens change, will this decrease over time? What are the emetogenic agents that cause CINV most frequently, judging from your experience?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.